Kimberly Brandt1, Kaitlin McGinn2, Jeffrey Quedado3. 1. Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA St Joseph's Regional Medical Center, Paterson, NJ, USA gathersk@sjhmc.org. 2. Auburn University, Harrison School of Pharmacy, Mobile, AL, USA University of South Alabama Medical Center, Mobile, AL, USA. 3. West Virginia University Healthcare, Morgantown, WV, USA.
Abstract
OBJECTIVE: To review and evaluate the evidence regarding the use of low-dose regimens of alteplase (tPA) for the treatment of pulmonary embolism (PE). DATA SOURCES: A PubMed search (1966-January 2015) was conducted using the search terms pulmonary embolism, drug therapy, thrombolytic therapy, fibrinolytic agents, and tissue plasminogen activator. Articles were cross-referenced for additional citations. STUDY SELECTION AND DATA EXTRACTION: Clinical trials and case reports published in the English language assessing the use of low-dose systemic tPA for the treatment of PE were reviewed for inclusion. DATA SYNTHESIS: tPA is a thrombolytic agent indicated for the treatment of massive and submassive PE. Major bleeding complications of tPA are dose dependent and may occur in up to 6.4% of patients. Clinical trials have demonstrated safety and efficacy of low-dose tPA, particularly showing its benefit in patients with a low body weight (<65 kg) and right-ventricular dysfunction. Furthermore, case reports have safely used lower doses of tPA in patients at higher risk of bleeding, including elderly, pregnant, and surgical patients. CONCLUSIONS: The available data suggest that low-dose tPA may be a safe and effective treatment option for acute PE, particularly in patients at a high risk of bleeding. More studies are needed to determine the optimal dosing regimen of tPA for PE.
OBJECTIVE: To review and evaluate the evidence regarding the use of low-dose regimens of alteplase (tPA) for the treatment of pulmonary embolism (PE). DATA SOURCES: A PubMed search (1966-January 2015) was conducted using the search terms pulmonary embolism, drug therapy, thrombolytic therapy, fibrinolytic agents, and tissue plasminogen activator. Articles were cross-referenced for additional citations. STUDY SELECTION AND DATA EXTRACTION: Clinical trials and case reports published in the English language assessing the use of low-dose systemic tPA for the treatment of PE were reviewed for inclusion. DATA SYNTHESIS: tPA is a thrombolytic agent indicated for the treatment of massive and submassive PE. Major bleeding complications of tPA are dose dependent and may occur in up to 6.4% of patients. Clinical trials have demonstrated safety and efficacy of low-dose tPA, particularly showing its benefit in patients with a low body weight (<65 kg) and right-ventricular dysfunction. Furthermore, case reports have safely used lower doses of tPA in patients at higher risk of bleeding, including elderly, pregnant, and surgical patients. CONCLUSIONS: The available data suggest that low-dose tPA may be a safe and effective treatment option for acute PE, particularly in patients at a high risk of bleeding. More studies are needed to determine the optimal dosing regimen of tPA for PE.
Authors: Tyree H Kiser; Ellen L Burnham; Brendan Clark; P Michael Ho; Richard R Allen; Marc Moss; R William Vandivier Journal: Crit Care Med Date: 2018-10 Impact factor: 7.598
Authors: Samuel A Hendley; Alexey Dimov; Aarushi Bhargava; Erin Snoddy; Daniel Mansour; Rana O Afifi; Geoffrey D Wool; Yuanyuan Zha; Steffen Sammet; Zheng Feng Lu; Osman Ahmed; Jonathan D Paul; Kenneth B Bader Journal: Sci Rep Date: 2021-11-23 Impact factor: 4.379
Authors: Parth V Desai; Nicolas Krepostman; Matthew Collins; Sovik De Sirkar; Alexa Hinkleman; Kevin Walsh; Jawed Fareed; Amir Darki Journal: Curr Neurol Neurosci Rep Date: 2021-10-20 Impact factor: 5.081